Laddar...
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refra...
Sparad:
| I publikationen: | Drug Des Devel Ther |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4376183/ https://ncbi.nlm.nih.gov/pubmed/25848209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S82007 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|